Clinical trials: CNV
Choroidal Neovascularization in Angioid Streaks
Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).
Angioid streaks are rare lesions associated to retinal pigment epithelium degenerations. They can be caused by general diseases as pseudoxanthoma elasticum, Paget's disease or drepanocytosis.
- Trial name
- ASTRID (NCT02573038)
- Testing
- Aflibercept
- Sponsor
- Hospices Civils de Lyon
Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.
- Trial name
- PALLAS (NCT07389980)
- Testing
- aflibercept 8 mg
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yeungnam University College of Medicine
Polypoidal Choroidal Vasculopathy
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (NV AMD), is an important cause of central visual loss, especially among Asian and African descendants.
- Trial name
- NCT04707027
- Testing
- Aflibercept Injection (2 mg/0.05 ml), Defer treatment
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Chiang Mai University
Genetic Diseases
Prenatal Microarray Follow-Up Study
The objectives of this multi-center collaborative study are to ascertain the frequency of specific copy number variants (CNVs) identified prenatally and to evaluate in detail through continued follow-up of the children the…
- Trial name
- NCT02160938
- Testing
- 3-year follow-up
- Where
- 9 sites in United States
- Volunteers
- 184 people
- Sponsor
- Columbia University
Macular Degeneration, Choroidal Neovascularization
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with…
- Trial name
- NCT00433017
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 12 sites in Austria, Belgium and 10 more
- Volunteers
- 255 people
- Sponsor
- Novartis
Choroidal Neovascularization
Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal neovascularization. Minimum follow-up 12 months.
- Trial name
- NCT02015351
- Testing
- bevacizumab
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- University of Sao Paulo
Choroidal Neovascularization
TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration
The purpose of the study is to compare photodynamic therapy to transpupillary thermotherapy as a treatment method for choroidal neovascularization in age-related macular degeneration ( AMD).
- Trial name
- NCT00260403
- Testing
- Photodynamic therapy versus Transpupillary thermotherapy
- Where
- Sweden
- Volunteers
- 140 people
- Sponsor
- St. Erik Eye Hospital
Epiretinal Membrane, Age Related Macular Degeneration
Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes
Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
- Trial name
- NCT01846351
- Volunteers
- 16 people
- Sponsor
- New England Retina Associates
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Macular Degeneration
Comparison of Reduced Fluence Versus Standard Photodynamic Therapy (in Combination With Intravitreal Triamcinolone Acetate)
To assess the CNV treatment effect of PDT with verteporfin in combination with IVTA using reduced fluence compared to the standard fluence.
- Trial name
- NCT00523406
- Testing
- Photodynamic therapy and intravitreal triamcinolone
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Vienna
Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
Macular neovascular diseases including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), pathological myopia (PM) and etc. can cause severe vision loss.
- Conditions
- Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, Pathological Myopia, Conbercept
- Trial name
- NCT03128463
- Testing
- Intravitreal injection of conbercept
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Xun Xu
Macular Degeneration, Histoplasmosis
Submacular Surgery Trials (SST)
To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV…
- Trial name
- NCT00000150
- Testing
- Subfoveal Choroidal Neovascularization Removal
- Sponsor
- National Eye Institute (NEI)
Idiopathic Choroidal Neovascularization
Intravitreal Conbercept for Idiopathic Choroidal Neovascularization
The purpose of this study is to evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy as primary treatment for ICNV.
- Trial name
- NCT02857517
- Testing
- conbercept
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiao Mingfei
Myopic Choroidal Neovascularization, VEGF Aqueous Level
VEGF and PEDF in Patients With Myopic Choroidal Neovascularization
This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in eyes with mCNV treated with IVB.
- Conditions
- Myopic Choroidal Neovascularization, VEGF Aqueous Level, PEDF Aqueous Level
- Trial name
- NCT02175940
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Università degli Studi di Brescia
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in…
- Trial name
- STAIRWAY (NCT03038880)
- Testing
- Faricimab, Ranibizumab
- Where
- 25 sites in United States
- Volunteers
- 76 people
- Sponsor
- Hoffmann-La Roche
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal…
- Trial name
- NCT01944839
- Testing
- E10030, ranibizumab
- Where
- 115 sites in United States, Austria and 11 more
- Volunteers
- 619 people
- Sponsor
- Ophthotech Corporation
Obesity, Metabolic Syndrome
Genetics of Obesity in Chinese Youngs
The purpose of this study is to explore the pathogenesis and genetic susceptibility of obese subjects,providing a convincing argument for further treatment of obesity and metabolic syndrome.
- Trial name
- GOCY (NCT01084967)
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Age-Related Macular Degeneration
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.
- Trial name
- NCT02387957
- Testing
- Fovista®, bevacizumab, ranibizumab
- Where
- 24 sites in United States
- Volunteers
- 63 people
- Sponsor
- Ophthotech Corporation
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
Study the effectiveness of the treatment detachment of retinal pigment epithelium secondary to polypoidal choroidal vasculopathy. Efficacy will be assessed by regression of polyp area after twelve months, compared to baseline.
- Trial name
- NCT01666236
- Testing
- Triple Therapy
- Where
- Brazil
- Sponsor
- Federal University of São Paulo
Choroidal Neovascularization, Degenerative Myopia
Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study is to see if the drug bevacizumab is safe and effective to use for people with choroidal neovascularization (CNV).
- Conditions
- Choroidal Neovascularization, Degenerative Myopia, Pathological Myopia
- Trial name
- NCT00407719
- Testing
- Bevacizumab
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University